The nuclear factor kappa B p50 subunit and cortactin as markers to distinguish between keratoacanthoma and well‐differentiated squamous cell carcinoma

Background.  Distinguishing keratoacanthoma (KA) from well‐differentiated squamous cell carcinoma (SCC) is sometimes difficult. Recent evidence indicates that the nuclear factor kappa B p50 subunit (p50) and cortactin might be useful to distinguish between these two conditions.

[1]  H. Takahashi,et al.  Subungual keratoacanthoma: analysis of cell proliferation and copy number variation of oncogenes compared with periungual squamous cell carcinoma , 2011, Clinical and experimental dermatology.

[2]  A. Yap,et al.  Cortactin: Coordinating adhesion and the actin cytoskeleton at cellular protrusions. , 2009, Cell motility and the cytoskeleton.

[3]  J. Oxley,et al.  Immunohistochemical staining for the differentiation of subungual keratoacanthoma from subungual squamous cell carcinoma , 2008, Clinical and experimental dermatology.

[4]  D. Ribeiro,et al.  Expression of apoptotic and cell proliferation regulatory proteins in keratoacanthomas and squamous cell carcinomas of the skin. , 2008, Pathology, research and practice.

[5]  A. Khachemoune,et al.  Keratoacanthoma: a tumor in search of a classification , 2007, International journal of dermatology.

[6]  H. Pasolli,et al.  p120-Catenin Mediates Inflammatory Responses in the Skin , 2006, Cell.

[7]  E. Fuchs,et al.  Links between α-catenin, NF-κB, and squamous cell carcinoma in skin , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  T. Saida,et al.  Genome profiling of melanocytic tumors using multiplex ligation-dependent probe amplification (MLPA): Its usefulness as an adjunctive diagnostic tool for melanocytic tumors. , 2005, Journal of dermatological science.

[9]  M. Slater,et al.  Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers , 2005, Histopathology.

[10]  Joanne E Curran,et al.  Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. , 2002, Cancer letters.

[11]  P. Leboit.  Can we understand keratoacanthoma? , 2002, The American Journal of dermatopathology.

[12]  T. Tsuji.  Keratoacanthoma and squamous cell carcinoma: study of PCNA and LeY expression , 1997, Journal of cutaneous pathology.

[13]  Michael J. Costa,et al.  Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior. , 1996, Human pathology.

[14]  G. Halliday,et al.  Evidence that regression in Keratoacanthoma is immunologically mediated: a comparison with squamous cell carcinoma , 1994, The British journal of dermatology.

[15]  Robert E. Jones,et al.  Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. , 1993, The American Journal of dermatopathology.

[16]  J. Parsons,et al.  Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex , 1993, The Journal of cell biology.

[17]  M. Goldenhersh,et al.  Invasive squamous cell carcinoma initially diagnosed as a giant keratoacanthoma. , 1984, Journal of the American Academy of Dermatology.

[18]  S. Cramer,et al.  Subungual keratoacanthoma. A benign bone-eroding neoplasm of the distal phalanx. , 1981, American journal of clinical pathology.

[19]  T. Batinac,et al.  Possible key role of granzyme B in keratoacanthoma regression. , 2006, Medical hypotheses.

[20]  Susan J Wilson,et al.  Nuclear Factor-(cid:2) B1 (p50) Limits the Inflammatory and Fibrogenic Responses to Chronic Injury , 2022 .